1. As of noon trading, Medtronic ( MDT) is up $0.42 (0.9%) to $45.96 on average volume Thus far, 2.4 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.5 million shares. The stock has ranged in price between $45.28-$45.97 after having opened the day at $45.33 as compared to the previous trading day's close of $45.54.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $45.7 billion and is part of the health services industry. The company has a P/E ratio of 13.8, below the S&P 500 P/E ratio of 17.7. Shares are up 10.0% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Medtronic a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Medtronic Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

IPOs That Should Be on Your Radar

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting